


[Home](#) | [Contact Us](#) | [Login](#)
National Collegiate Inventors  
& Innovators Alliance

**SCHEDULE**

[^](#)  
 AI2V 1: Waltham, MA 8/1-4  
 AI2V 2: Urbana, IL 9/9-12  
 Southfield, MI - 9/28  
 Kansas City, MO - 9/29  
 St. Paul, MN - 10/6  
 Fargo-Moorehead, MN - 10/12  
 Colorado, CO - 11/2  
[v](#)

[About Us](#)
[Events](#)
[Resources](#)
[Archives](#)
[Purchase the I2V  
Participant Guide](#)
[Read our Weblog](#)
[Contact I2V](#)

MADE POSSIBLE BY:


 Ewing Marion  
**KAUFFMAN**  
 Foundation

**ARCHIVES - 2005**
**University of California at San Diego: 2005 Speaker Profiles**

To learn more about each speaker, simply click on their name.

[Gari Cheever](#)  
[Eric Donsky](#)  
[Eleazar Eskin](#)  
[Stephen Flaim, Ph.D.](#)  
[Jack Florio](#)  
[Wayne Giles](#)  
[David F. Hale](#)  
[Dr. Paul S. Kedrosky](#)  
[Denise Lew](#)  
[Robert F. Mattrey](#)  
[Richard Mejia, Jr.](#)  
[Steven Richieri](#)  
[John Rodenrys](#)  
[Tim Rueth](#)  
[Chris Steinhardt](#)  
[Judith L. Swain, M.D.](#)  
[David Urso](#)  
[John Watson](#)  
[Diane West](#)


**Gari Cheever - Corporate Finance, Corporate Law & Governance**

Gari Cheever is a partner in the San Diego office of Wilson Sonsini Goodrich & Rosati. Prior to joining the firm, Gari was President and Chief Executive Officer of Kinzan, Inc., a San Diego-based web services software company, which he joined in 1999. During his tenure at Kinzan, he was involved in all aspects of the company's operations, from securing \$40 million in venture capital funding to preparing for an initial public offering.

From 1997 to 1999, Gari was Executive VP and Chief Financial Officer of Encanto Networks, where he managed the raising of over \$50 million in venture capital, negotiated strategic relationships with several Fortune 100 companies, and oversaw all the company's legal affairs and corporate development activities.

Prior to his work at Encanto, Gari was a partner in the Palo Alto office at Brobeck, Phleger & Harrison. Gari has broad experience in the general corporate representation of high-growth technology companies, public corporations, venture capital, private equity firms, and investment banks. He has represented a wide variety of companies-ranging from start-ups to Fortune 500s-in hundreds of transactions. Gari has worked on more than 75 mergers and acquisitions, 100 public offerings in equity and convertible securities for issuers and underwriters, and 200 private financings for companies, venture capitalists, private equity firms, and investment banks. His representative public companies included Polycom, Microchip Technologies, Intevac, and Cisco Systems, each of which he represented from early startup through IPO and as large public companies. As part of Gari's representation of Cisco, he was involved at all stages of the company's growth, including implementing the company's aggressive acquisition strategy and acted as counsel to their first 15 transactions. He has represented many of the leading venture capital investors and investment bankers, including Kleiner, Perkins, Caufield & Byers; Sequoia Capital; Accel Partners; Mayfield; Redpoint (fka IVP); NEA; Mohr Davidow; Sierra Ventures; Menlo Ventures; Goldman Sachs; CSFB; Morgan Stanley; Merrill Lynch, Lehman Brothers; and JP Morgan Chase & Co.

Gari earned a J.D. degree from Stanford Law School in 1983 and two B.S. degrees, with honors, from Arizona State University in 1980. He is a member of the State Bar of California and the American Bar Association as well as the State Bar of Colorado. Gari is currently the Chairman of the Board of the San

Diego Software Industry Council and serves on the board of directors of the San Diego Regional Economic Development Corporation.

[Back to Top](#)



**Eric Donsky - President and CEO, OcuSense Corporation**

Eric Donsky has 15 years experience in the development of early-stage biotechnology and life science companies as a founder and senior manager. Eric is currently the CEO of OcuSense, Inc., an ophthalmic device company commercializing novel, laboratory-on-a-card technologies that enable eye care practitioners to test for highly sensitive and specific biomarkers in tears at the point-of-care so physicians can personalize treatment and objectively track patient outcomes. The first target market for the Company is dry eye syndrome, an ocular surface disease that afflicts over 30 million Americans. Presently, less than 5% of this patient population is diagnosed and there are 14 drugs in various phases of clinical development indicated for dry eye. OcuSense has conducted a clinical trial at Shiley Eye Center that demonstrated that the Company's technology was repeatable and capable of differential diagnosis with statistical significance. The Company is currently developing a commercial product, in collaboration with Micronics and Invetech, and expects to launch by 2 nd quarter 2007. Eric is also a principal of Molecular BioSciences (MBI), a life science incubator and consulting practice. Recently, MBI licensed a novel cardiac output monitor to Medtronic capable of measuring arterial blood flow and pulseless electrical activity (PEA), during defibrillation and CPR, of those patients experiencing sudden cardiac arrest.

Previously, Eric was the founding CEO of Zolaris BioSciences, Inc., an early-stage biotechnology company focused on the discovery and development of therapeutics for the treatment of rheumatoid arthritis (RA), multiple sclerosis (MS), and infectious diseases. Zolaris had in-licensed technology from the University of Georgia that had proven in both in-vitro and in-vivo models to significantly increase the stability and duration of therapeutic activity of peptides without adversely affecting their biological activity. This technology is being used to increase the stability of existing peptide therapeutics and is also being leveraged as a forward genetics approach for the discovery of novel drug candidates. Prior to Zolaris, Eric was the founding CEO of Applied CarboChemicals, Inc. ("ACC"), a biotechnology company focused on the commercial development of novel fermentation processes capable of manufacturing unique compounds that have application in the food, chemical, and pharmaceutical industries. During his tenure as CEO, ACC closed its Series A and Series B rounds of equity financing, secured an \$8.8 million Cooperative Research And Development Agreement (CRADA) with the U.S. Department of Energy, established research and licensing agreements with several government and university laboratories, and formed both process and product development alliances with several collaborative partners. ACC was a recipient of the 1997 R&D 100 Award in recognition of its platform process technology. ACC currently has manufacturing operations and has several products on the market. ACC is venture-backed and Toyota is the Company's largest corporate investor. Mr. Donsky graduated from Boston University in 1987 with a B.S. in Business Administration.

[Back to Top](#)



**Eleazar Eskin - Assistant Professor in Residence, Computer Science & Engineering, UCSD**

Research Focus: Computational biology and bioinformatics, and specifically, applications of machine learning and algorithms to problems in biology.

Prior to joining the CSE department in 2003, Eleazar Eskin was a post-doctoral researcher at the Hebrew University of Jerusalem in computer science with professors Yoram Singer and Nir Friedman. He completed his Ph. D. in Computer Science at Columbia University in 2001 (ck), where he did his thesis on "Sparse Sequence Modeling with Applications to Computational Biology and Intrusion Detection." At Columbia, Eskin was a member of the Natural Language Processing group prior to joining the Data Mining Lab, and later was in the Computational Biology group. Professor Eskin has helped develop multiple software and Web-based programs to improve the understanding of the genetic basis for complex diseases via modeling of human variation.

[Back to Top](#)



**Stephen Flaim, Ph.D. - Technology and Business Advisor, von Liebig Center Jacobs School of Engineering, UCSD**

Stephen Flaim, Ph.D., - needs no introduction to many at the Jacobs School. Steve received his graduate degree in Human Physiology and Pharmacology from the University of California at Davis and subsequently assumed a faculty position in Medicine and Physiology at the Pennsylvania State University College of Medicine at Hershey, PA. His industry research includes positions McNeil Pharmaceutical, Squibb Institute for Medical Research, Alliance Pharmaceutical Corporation and Trega Biosciences, Inc.

Dr. Flaim is currently Senior Vice President of Research & Development at Galileo Laboratories, Inc. located in Santa Clara, CA. Galileo Laboratories is developing therapeutic agents for the treatment of stroke, cardiovascular disease, diabetes and inflammation. Dr. Flaim is a Fellow of the American College of Cardiology and of the American College of Clinical Pharmacology.

[Back to Top](#)

**Jack Florio - Vice President, Tech Coast Angels**

Jack was one of the founding members of the BioMedTrak group of San Diego Tech Coast Angels and actively involved in the development and implementation of their Life Sciences strategy. In addition to deal analysis and due diligence team leadership, he is responsible for communications and public relations for the SDTCA.

Jack serves on the Board of Directors of ChemNavigator, a privately held biotechnology company focused on drug discovery. Jack is also currently very active with a variety of organizations which promote the development of entrepreneurship and capital formation focused on emerging science and technology in the life sciences community in San Diego. These include the CONNECT Springboard and Mentoring Programs, and the Life Sciences Financial Forum. Jack is also a member of BIOCOM where he is active on the Financial Community Relations Committee, the Life Sciences Venture Network Subcommittee, and the Capital Formation Committee. Jack is on the Steering Committee for the San Diego Telecom Council (SDTC) Healthcare Communications Technology SIG. He also works with the San Diego Regional Technology Alliance (SDRTA) where he has serves on the review committee for Venture Roundtable and is actively involved in a number of programs with the Entrepreneurial Management Center at San Diego State University.

Additionally Jack is an active member of the San Diego Venture Group (SDVG), The Indus Entrepreneurs (TiE), the San Diego MIT Enterprise Forum (SDMIT) and other organizations which foster the evolution of science and technology from the lab, combining them with potential sources of funding and developing them into emerging companies.

Jack continues to assume senior management roles in emerging companies helping them develop strategies and implement those plans to get them to the next level of business, organizational, and corporate development. He has taken positions in six companies, assuming a variety of roles. Two of these are currently active, Vital Therapies, Inc and Aegis Therapeutics, LLC. Prior to this, Jack was in a variety of leadership positions (Business Development, Product Development, and CEO) with InJet Digital Aerosols here in San Diego.

Before coming to San Diego in 2001, Jack completed a successful 30 year career with Eli Lilly and Company where he was in senior leadership positions in Marketing, Market Research, Sales Management, Business Development, Worldwide Pricing Development, Business Unit Leadership, and other management roles both domestically and outside the US.

Jack has a B.S. in Pharmaceutical Sciences from Columbia University and an MBA from New York University.

[Back to Top](#)

**Wayne Giles - Professor, Bioengineering**

Dr. Wayne Giles is a major contributor to present understanding of electrical impulses that initiate and modulate the heart beat. A leader in addressing questions concerning pacemaker activity and cardiac arrhythmia, Giles' work provides insight into the design of cardiac pacemakers and defibrillators, as well as drugs which control dangerous heart rhythms, which left unchecked, can lead to heart attacks. He is a long-time collaborator with UCSD School of Medicine's, Dr. Kenneth Chien, and Dr. W. Dillmann, and together they have studied animal models of sudden cardiac death and thyroid hormone disorders. Giles and his colleagues have developed a computational model of human atrial electrophysiology and this model is now being used for undergraduate and graduate education as well as compound screening and drug discovery. Giles is also involved in fundamental research on the structure and function of ion channels, and ion transport mechanisms that, for example, carry into the cell the calcium needed for each heartbeat. Many diseases of the heart are caused by ion channel malfunction.

Specialty areas: Electrophysiology, pharmacology and biophysics of cardiac cells, and their role in heart rhythm and arrhythmias. Mathematical modeling.

Capsule Bio:

Wayne Giles joined UCSD in 2003 with a joint appointment as a Professor of Bioengineering and of Medicine. Most recently, Giles was the Head of the Department of Physiology and Biophysics at the University of Calgary where he held an Endowed Chair from the Heart and Stroke Foundation of Alberta. He was a Professor at the University of Calgary from 1983 to 2002, and previously a Faculty member of the University of Texas (Galveston) Faculty of Medicine. Giles serves on the editorial boards of Circulation Research and the American Journal of Physiology. He received his Ph.D. in Physiology from Yale University in 1974.

[Back to Top](#)

**David F. Hale - President and CEO, CancerVax**

Mr. Hale has served as our President and Chief Executive Officer since October 2000 and as a member of our Board of Directors since December 2000. From January 1998 to May 2000, Mr. Hale served as President and Chief Executive Officer of Women First HealthCare, Inc., a publicly-traded specialty pharmaceuticals company. Prior to joining Women First HealthCare, Mr. Hale served from May 1987 to November 1997 as Chairman, President and Chief Executive Officer of Gensia, Inc., a publicly-held

biopharmaceutical company, which is now known as Sicor, Inc., and also served from February 1987 to September 1994 as Chairman of Viagene, Inc., a publicly held biotechnology company that was acquired by Chiron, Inc. Mr. Hale served from April 1982 to May 1987 in several positions with Hybritech, Inc., a publicly-traded biotechnology company that was acquired by Eli Lilly and Co., including Senior Vice President of Marketing and Business Development, Chief Operating Officer and ultimately President and Chief Executive Officer. Prior to joining Hybritech, Mr. Hale served from January 1980 to April 1982 as Vice President, Sales and Marketing and then as Vice President and General Manager with BBL Microbiology Systems, a division of Becton, Dickinson & Co. From March 1971 to December 1980, Mr. Hale held various marketing and sales management positions with Ortho Pharmaceutical Corporation, a division of Johnson & Johnson, Inc. Mr. Hale currently serves as a director of several privately-held biotechnology companies, including, Xcel Pharmaceuticals, Inc., Santarus, Inc., Metabasis Therapeutics, Inc., LMA North America, Inc. and SkinMedica, Inc. Mr. Hale also serves as Chairman of BIOCUM/San Diego, a major regional trade association for the life sciences industry, of which Mr. Hale was a founder, and serves on the Board of the California Healthcare Institute and the BIO Emerging Growth Companies Section Governing Body. He is a founder of the UCSD CONNECT Program in Technology and Entrepreneurship and currently serves on the CONNECT Leadership Council. Mr. Hale received a B.A. in biology and chemistry from Jacksonville State University.

[Back to Top](#)



**Dr. Paul S. Kedrosky - Executive Director, von Liebig Center Jacobs School of Engineering, UCSD**

Dr. Paul Kedrosky has been appointed Executive Director of the von Liebig Center in the Jacobs School of Engineering. Dr. Kedrosky has extensive experience in entrepreneurship, finance, venture capital, and academia.

Dr. Kedrosky advises venture capital firms in the U.S. and Canada, and has been a venture partner with Ventures West, a \$500-million venture firm, as well as having been a board-member of various technology companies. He founded the technology equity research practice at HSBC James Capel ( Canada ), a subsidiary of one of the largest brokerage firms in the world.

Technology transactions with which he was involved created in excess of \$3-billion in public market value. Dr. Kedrosky continues to be on the board of advisors of companies in the U.S. and Canada, in addition to having founded three companies of his own. He has also been a faculty member at the University of British Columbia in Vancouver, Canada.

Dr. Kedrosky has published more than 300 articles in academic and non-academic publications on venture capital, entrepreneurship, and innovation. He has appeared on many media outlets, including CNN, CNBC, PBS Newshour, and ABC Nightline, as well as having been interviewed by the New York Times, the Wall Street Journal, and many other publications. He has also written for the Economist, the Wall Street Journal, the Brookings Institute Review, Forbes, the Harvard Business Review and the National Post.

Dr. Kedrosky divides his time between San Diego, California, and Vancouver, British Columbia.

[Back to Top](#)



**Denise Lew - Senior Licensing Officer, TechTIPS, UCSD**

Denise originates from Texas and obtained her B.A. in biology in Dallas . Following several years of lab work as a research assistant in the Stanford biochemistry department, she earned her Ph.D. in biochemistry from the University of Illinois . After graduate school, she eagerly moved to San Diego and conducted her postdoctoral research at the Salk Institute, creating transgenic mice to study the developmental regulation of mammalian gene expression. She then transitioned into the San Diego biotech industry where she acquired 10 years' experience as a research scientist in molecular biology and pharmacology. Her investigations included developing gene therapies for cancer and infectious diseases.

Denise maintains philanthropic involvement in the San Diego community. She serves on the Board of Governors for the San Diego Foundation and is the vice-chair of their Science and Technology group, which distributes grants to address local needs in science education and research. She is also a founding member of the San Diego Women's Foundation and serves on their Education committee. When she has the time, Denise particularly enjoys international travel where she takes the opportunity to scuba dive and makes attempts at underwater photography. She is a member of the San Diego Underwater Photographic Society, where she serves as its treasurer and membership officer.

[Back to Top](#)



**Robert F. Mattrey, MD**

Robert Mattrey is a Professor of Radiology at UCSD Medical Center, in the Department of Radiology. Dr. Mattrey's main focus in radiology research has contributed to his being given the position of Vice Chairman of Radiology, Director of Research. He is also the Director of In-vivo Cellular and Molecular Imaging Program, Director of Core Resources, Clinical Investigational Institute at UCSD and the Director of Body MRI. Along with research and clinical trials, his clinical duties include General Radiology and Body Imaging (CT/US/MRI).

Dr. Mattrey was educated at the State University of New York at Buffalo where in 1971 he received a B.S. in Electrical Engineering. In 1973, he obtained an M.S. in Electrical Engineering, at the State University New York at Buffalo. He received his medical degree from the State University of New York at Buffalo in 1978. His Residency in Diagnostic Radiology, was completed through the University of California, San Diego, Dept. of Radiology in 1978-81 where he was elected Chief Resident. His Fellowship training in CT/Ultrasound/Interventional, were also completed at the University of California, San Diego, Department of Radiology in 1981-82.

Currently Dr. Mattrey maintains an active laboratory at UCSD in Hillcrest and the Cancer Center, in La Jolla. His research has recently focused on molecular imaging with particular emphasis on ultrasound contrast and the development of new instrumentation.

At the national and international level, Dr. Mattrey is viewed as an expert body imager with special expertise in contrast media in general, and ultrasound contrast in particular. He has been invited to lecture at many national and international meetings. Dr. Mattrey serves as an advisor to industry to establish business strategy. He has recently been asked to serve on a Committee of the American Institute of Ultrasound in Medicine to establish a liaison with the Food and Drug Administration to educate the FDA on the benefits of ultrasound contrast in order to speed their entry and availability to the American public for radiological applications.

[Back to Top](#)



**Richard Mejia, Jr. – Partner, Director – Life Sciences, San Diego, California**

Rich is the Director of Life Sciences in the Pacific Southwest area. Rich services both public and emerging growth companies.

With more than 30 years at Ernst & Young, he has extensive experience with IPOs and other equity and debt offerings as well as mergers and acquisitions. Some of the public life science clients Rich serves include: Invitrogen Corporation, Neurocrine Biosciences, Discovery Partners International, CancerVax Corporation and SkinMedica.

Rich is a graduate of the University of Southern California and serves on the Board of Directors BIOCUM as well as its Executive Committee. For seven years he also served on the Board of the San Diego Venture Group.

[Back to Top](#)



**Steven Richieri – President and CEO, American Life Sciences Pharmaceuticals, Inc.**

Steven Richieri is a founder and Managing Director of Beachhead. Mr. Richieri has over 20 years of experience in the healthcare industry, and has a broad background in biotechnology, pharmaceutical and medical device product development and corporate collaborations.

Mr. Richieri is a co-founder of two life science companies, American Life Science Pharmaceuticals and NuVista Technology Corporation, and consults with a number of companies regarding a wide range of product and corporate development activities. Mr. Richeiri has successfully filed nine Investigational New Drug applications and has conducted numerous Phase I-III clinical trials in the areas of HIV, autoimmune diseases, allergic rhinitis, and cancer. Mr. Richieri directed the design and construction of a 50,000 ft<sup>2</sup> cGMP commercial scale BSL-3 manufacturing facility for the production of a parenteral biological product. He successfully prepared Pre-market Approval Applications and 510k submissions for Class I, II, and III medical devices.

Mr. Richieri has held senior executive positions at The Immune Response Corporation and Dura Pharmaceuticals, and currently serves as Senior Vice President of Regulatory Affairs and Product Development at Egea Biosciences. Mr. Richieri holds a degree in Pharmacy from Rutgers College of Pharmacy and an M.B.A from the University of San Diego.

[Back to Top](#)



**John Rodenrys - CEO and Senior Managing Partner of Leading Ventures LLC**

Mr. Rodenrys has had extensive leadership positions in several significant companies. Mr. Rodenrys is CEO and Senior Managing Partner of Leading Ventures LLC , [www.leadingventures.com](http://www.leadingventures.com), a venture fund which identifies early stage technologies that can be accelerated to a revenue generating entity, early outlicense or sale to an acquiring firm. Previously, he was CEO of SafetyMate Corporation, the company that invented and distributes a portable life saving responder device with American Red Cross and Homeland Security Protocols. Prior to joining SafetyMate, he was COO of ForHealth Technologies where he was responsible for R&D, manufacturing, quality assurance, customer service and field operations. Before ForHealth Technologies, he served as president of Vistant Corporation, a subsidiary of Cardinal Health (NYSE:CAH), and a Fortune 50 Company. He previously served as VP R&D and IT for Pyxis Corporation, a subsidiary of Cardinal Health (NYSE:CAH) and as VP Development for MicroMRP, a LAN-based enterprise software company. He is an active member of the Keiretsu Forum and the San Diego Tech Coast Angels. He holds a BS in engineering from Rensselaer Polytechnic Institute (RPI), a master's in Management Science from US International University (USIU) and an APICS CPIM ( American Production & Inventory Control Society: Certified in Production & Inventory Management. He

is the co-author of Production and Management Systems for Business , published by Prentice Hall and is the co-inventor on two patents.

[Back to Top](#)



**Tim Rueth - President and CEO - Rhevision Technology, Inc.**

Tim Rueth's professional career includes excelling in an entrepreneurial environment as an engineer, executive, consultant, advisor, board member, and investor in small companies, as well as large company experience. His technical foundation began with design, development and management experience in the areas of custom integrated circuit design and wireless systems. His most recent experience includes technology and business development, product commercialization, both sides of fund-raising, due diligence, deal structure, and small company investment. He is a private investor in San Diego and has served on the Board of Directors of the San Diego Tech Coast Angels, as well as the organization's Screening Committee, personally screening over 350 funding applications. He was a co-founder and currently is the President and CEO of Rhevision Technology, Inc., and is an advisor to two other high-tech companies.

Mr. Rueth has been under contract with the University of California , San Diego , for over three years as a Technology and Business Advisor to commercialize technologies being developed within the Jacobs School of Engineering. Here, he has been instrumental in generating business strategies and industry interest in numerous University technologies as well as the formation of several start-up companies.

Prior to his consulting/advising and private investing activities, Mr. Rueth was Vice President, IC Engineering , for start-up SCS Corporation. Prior to this, he was Vice President, Strategic Technology , for Qualcomm's ASIC Business Unit (now Qualcomm CDMA Technologies), and prior to this, he was a Senior Engineer at Hewlett Packard Company.

[Back to Top](#)



**Chris Steinhardt - Partner, Knobbe Martens and Bear**

Chris Steinhardt is a partner in our San Francisco and San Diego offices. Mr. Steinhardt joined the firm in 2000 as of counsel and became a partner in 2003.

Prior to joining the firm, Mr. Steinhardt was of counsel and a partner with a biotechnology patent law firm. Before entering private practice, Mr. Steinhardt worked in the fields of molecular immunology and recombinant DNA as Director of Intellectual Property at Hybritech Incorporated (1988-1994). Mr. Steinhardt also worked in the pharmaceutical chemistry area as a patent attorney with Eli Lilly and Company (1979-1988). He has worked in the vaccine and protein/peptide chemistry area including protein therapy. Mr. Steinhardt's additional technology experience relates to biomedical devices, including diagnostic sensors and the chemical and biological detection methods, as well as understanding of the transgenic animal field.

**Education:**

Indiana University Law School (J.D. 1982) cum laude  
 Pennsylvania State University (M.S. Chemistry 1978)  
 Phi Lambda Upsilon Chemistry Honorary Society  
 Miami University (B.S. Chemistry 1976)

**Admissions/Qualifications:**

State of California  
 State of Indiana  
 Registered to practice before the U.S. Patent and Trademark Office

**Professional Memberships and Affiliations:**

American Bar Association, Intellectual Property Section  
 Chair, Chemical Practice Committee  
 Licensing Executives Society  
 American Chemical Society  
 American Intellectual Property Law Association  
 Association for Corporate Growth  
 San Diego County Bar Association

[Back to Top](#)



**Judith L. Swain, M.D., Dean for Translational Medicine and the Founding Director of the College of Integrated Life Sciences (COILS) – UCSD**

Dr. Judith L. Swain is Dean for Translational Medicine and the Founding Director of the College of Integrated Life Sciences (COILS) at the University of California, San Diego. Dr. Swain comes to UCSD from Stanford University after serving as Chair of the Department of Medicine and holding the Arthur Bloomfield and George E Becker Professorships. Prior to her appointment to Stanford in 1997, she was the Herbert C. Rorer Professor of Medical Sciences, Professor of Genetics, and Director of Cardiovascular Medicine at the University of Pennsylvania. Dr. Swain received her undergraduate education at the University of California, Los Angeles, and her medical education at the University of California, San Diego, before moving to Duke University for training in Internal Medicine and Cardiovascular Medicine. She then joined the faculty at Duke where she became widely known in the

field of molecular cardiology, and pioneered the use of transgenic animals to understand the genetic basis of cardiovascular development and disease. Her current research interests are centered on the regulation of vascular growth, and on assessing and enhancing human performance. She is currently Co-Director of the NASA National Center for Space Biological Technologies.

Dr. Swain has served in a number of national leadership roles, including president of the American Society for Clinical. She has served on the NIH Director's Standing Committee on Clinical Research, the NIH National Advisory Research Resources Council and the NRC Commission to evaluate the organization of the National Institutes of Health. She has served as a member of the NRC Committee on Space Biology and Medicine, and currently serves as a member of the Defense Science Research Council, and the Board of Army Science and Technology. Dr. Swain has also served on international advisory committees including the International Advisory Committees of the Wellcome Trust, British Heart Association, and UK Medical Research Council. She currently serves on the International Advisory Panel for Graduate Education of the Singapore Agency for Science, Technology and Research, and as a scientific advisor for the Defense Sciences Organization in Singapore. She serves as a Director of the Burroughs Wellcome Fund, and on the SAB of the the Doris Duke Charitable Foundation and the Pasarow Foundation. She serves as a director or member of the scientific advisory boards for a number of biomedical technology companies, and is co-founder of Synecor, LLC a medical device incubator company. Dr. Swain has been elected to a number of honorary societies including the Association of American Physicians, the American Society for Clinical Investigation and the Institute of Medicine.

[Back to Top](#)



**David Urso - Principal, Forward Ventures**

David Urso joined Forward Ventures in April of 2002, where he is a Principal. David's focus is identifying and researching investment opportunities for the firm. He has a scientific background in molecular biology and immunology and is an attorney with experience in corporate securities and strategic alliances in the life science industry. David is also the Chief Business Officer of Tioga Pharmaceuticals, Inc., a Forward Ventures portfolio company. David serves on the Board of Directors of Tioga Pharmaceuticals and is a Board Observer for Morphotek, Inc.

Before joining Forward Ventures, David was Director of Corporate Development and Legal Affairs at DNA Sciences, Inc., where he negotiated and executed corporate partnering, acquisition and equity transactions. He was also responsible for intellectual property and regulatory matters relating to the commercialization of pharmacogenetic products. From 1995 to 2000, David was an attorney at Wilson Sonsini Goodrich & Rosati LLP and at Cooley Godward LLP in Palo Alto, Calif., where he focused on corporate securities and strategic alliances involving private and publicly traded life science companies. David has worked as a research scientist in the Gene Expression Sciences Labs at SmithKline Beecham and at the University of Pennsylvania Medical School.

David received a J.D. from Harvard Law School and a B.A. in Molecular Biology and Philosophy from Reed College.

[Back to Top](#)



**John Watson - Associate Director, von Liebig Center Jacobs School of Engineering, UCSD**

Dr. John Watson is Associate Director, William J. vonLiebig Center for Entrepreneurism and Technology Advancement and Professor of Bioengineering at the University of California, San Diego. Dr. John Watson career began at the University of Cincinnati. He went on to attend the Southern Methodist University in Dallas, receiving a MSME while working as a Systems Engineer on the Ling-Temco-Vought XC-142 Vertical Takeoff Transport. He received a doctorate in Physiology from the University of Texas Southwestern Medical School in 1972. He was appointed an Assistant Professor in the Departments of Surgery and Physiology and Chairman of the Graduate Studies Program in Biomedical Engineering. In 1976, Dr. Watson joined the National Heart, Lung, and Blood Institute as Chief, Devices and Technology Branch. Dr. Watson had responsibilities for research and development of cardiovascular imaging systems, implantable materials, ventricular assist devices and the total artificial heart. He served as Acting NHLBI Deputy Director and Director of Clinical and Molecular Medicine until 2003, with oversight of 60 major clinical trials, genomics and proteomics, tissue engineering and regeneration, computational biology and informatics, and adult and pediatric circulatory support programs. He is a Founding Fellow of the American Institute for Medical and Biological Engineering, the first NIH scientist/engineer elected to the National Academy of Engineering and an invited member of the nominating committee for the Japanese Kyoto Prize and the NAE Draper Prize.

He was inducted into the National Academy of Engineering (NAE) in 1998, becoming the first member so recognized from the NIH. The diagnosis and treatment of heart failure remains his main clinical research area. He is recognized for the conception, design, development, and clinical trial of left ventricular assist devices and the artificial heart, and for contributing to the federal regulatory and payment decision-making process. Among his honors: He was an invited member of the Nominating Committee for the Nobel Prize, the Japanese Kyoto Prize, and the NAE Draper Prize.

Before coming fulltime to UCSD in December 2003, John T. Watson was NIH's Director of Clinical and Molecular Medicine of the National Heart, Lung, and Blood Institute. He oversaw 60 major clinical trials involving thousands of patients and contributed to advances in cardiovascular imaging, biomaterials, mechanical circulatory support devices, genomics and proteomics, tissue engineering and regeneration, computational biology and informatics, and randomized clinical trials. He received a Ph.D. in physiology from the University of Texas Southwestern Medical School in 1972.

[Back to Top](#)



**Diane West - President, 2Connect**

Diane West is President of 2Connect. For over 13 years, Diane has managed, designed and delivered presentation training for companies such as Washington Mutual Bank, Fair, Isaac and Elan Pharmaceuticals. Her track record is consistent – results, ranging from clients landing multi-million dollar contracts to companies securing significant funding.

Prior to founding 2Connect, Diane was the Vice President of Tamayo Consulting, Inc., a leadership training and development firm, where she designed and delivered training for companies such as Baxter Healthcare, Kyocera and Idec Pharmaceuticals. Prior to Tamayo Consulting, Diane led the training department of a \$70 million nationwide services company, Rescue Industries. In her role, she has managed and implemented training for over 1,000 employees nationwide in areas including communication, leadership, management, customer service and technical skills.

Diane has a B.A. in Economics from San Diego State University and holds certifications in Myers-Briggs, Temperament, AchieveGlobal and Leadership Management, Inc. She is actively involved in various community organizations including San Diego MIT Forum, UCSD CONNECT, UCSD Athena, BIOCUM, San Diego Venture Group and the San Diego Regional Technology Alliance.

[Back to Top](#)

[<Back to workshop](#)

---

NCIIA • 100 Venture Way, Hadley MA 01035 • Tel: 1.413.587.2172 • Fax: 1.413.587.2175 • [www.nciia.org](http://www.nciia.org) •  
[info@invention2venture.org](mailto:info@invention2venture.org)  
© 2005 NCIIA All Rights Reserved.